Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review

  • ID: 4395088
  • SWOT Analysis
  • 49 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Adaptimmune Ltd
  • Amgen Inc
  • Bristol- Myers Squibb Co
  • GlaxoSmithKline Plc
  • Juno Therapeutics Inc
  • Novartis AG
  • MORE
Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Iovance Biotherapeutics Inc (Iovance), formerly Lion Biotechnologies Inc is a biotechnology company that focuses on developing novel cancer immunotherapy products for treating various cancers. It develops products based on tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidate, LN-144 is an autologous, ready-to-infuse cell therapy. The product is an adoptive cell therapy using TIL technology and is being investigated in Phase II trials for treating patients with metastatic melanoma, recurrent and metastatic squamous cell carcinoma of the neck and head and recurrent and metastatic or persistent cervical cancer. The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.

Iovance Biotherapeutics Inc Key Recent Developments

Aug 06, 2018: Iovance Biotherapeutics reports second quarter 2018 financial results and provides corporate update
May 11, 2018: RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics
May 10, 2018: Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
Mar 12, 2018: Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
Mar 01, 2018: Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adaptimmune Ltd
  • Amgen Inc
  • Bristol- Myers Squibb Co
  • GlaxoSmithKline Plc
  • Juno Therapeutics Inc
  • Novartis AG
  • MORE
Section 1 - About the Company
Iovance Biotherapeutics Inc - Key Facts
Iovance Biotherapeutics Inc - Key Employees
Iovance Biotherapeutics Inc - Key Employee Biographies
Iovance Biotherapeutics Inc - Major Products and Services
Iovance Biotherapeutics Inc - History
Iovance Biotherapeutics Inc - Company Statement
Iovance Biotherapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis
Company Overview
Iovance Biotherapeutics Inc - Business Description
Iovance Biotherapeutics Inc - Corporate Strategy
Iovance Biotherapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Iovance Biotherapeutics Inc - Strengths
Iovance Biotherapeutics Inc - Weaknesses
Iovance Biotherapeutics Inc - Opportunities
Iovance Biotherapeutics Inc - Threats
Iovance Biotherapeutics Inc - Key Competitors

Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Iovance Biotherapeutics Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments
Aug 06, 2018: Iovance Biotherapeutics reports second quarter 2018 financial results and provides corporate update
May 11, 2018: RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics
May 10, 2018: Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
Mar 12, 2018: Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
Mar 01, 2018: Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day
Dec 13, 2017: BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics
Dec 13, 2017: Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017
Oct 31, 2017: Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results
Sep 07, 2017: Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center

Section 6 – Appendix
Methodology
Ratio Definitions
About
Contact Us
Disclaimer

List of Tables
Iovance Biotherapeutics Inc, Key Facts
Iovance Biotherapeutics Inc, Key Employees
Iovance Biotherapeutics Inc, Key Employee Biographies
Iovance Biotherapeutics Inc, Major Products and Services
Iovance Biotherapeutics Inc, History
Iovance Biotherapeutics Inc, Other Locations
Iovance Biotherapeutics Inc, Subsidiaries
Iovance Biotherapeutics Inc, Key Competitors
Iovance Biotherapeutics Inc, Ratios based on current share price
Iovance Biotherapeutics Inc, Annual Ratios
Iovance Biotherapeutics Inc, Annual Ratios (Cont...1)
Iovance Biotherapeutics Inc, Interim Ratios
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Iovance Biotherapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Iovance Biotherapeutics Inc, Performance Chart (2013 - 2017)
Iovance Biotherapeutics Inc, Ratio Charts
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Pfizer Inc
  • Bristol- Myers Squibb Co
  • GlaxoSmithKline Plc
  • Juno Therapeutics Inc
  • Adaptimmune Ltd
  • Novartis AG
  • Amgen Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll